Selective inhibition of JAK2-Driven erythroid differentiation of polycythemia vera progenitors

被引:113
作者
Geron, Ifat [1 ]
Abrahamsson, Annelie E. [1 ]
Barroga, Charlene F. [1 ]
Kavalerchik, Edward [1 ]
Gotlib, Jason [2 ]
Hood, John D. [3 ]
Durocher, Jeffrey [4 ]
Mak, Chi Ching [3 ]
Noronha, Glenn [3 ]
Soll, Richard M. [3 ]
Tefferi, Ayalew [5 ]
Kaushansky, Ken [1 ]
Jamieson, Catriona H. M. [1 ]
机构
[1] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[2] Stanford Univ, Dept Med, Stanford, CA 94305 USA
[3] TargeGen Inc, San Diego, CA 92121 USA
[4] Transgenomic Inc, Gaithersburg, MD 20878 USA
[5] Mayo Clin, Dept Med, Rochester, MN 55905 USA
关键词
D O I
10.1016/j.ccr.2008.02.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Polycythemia Vera (PV) is a myeloproliferative disorder (MPD) that is commonly characterized by mutant JAK2 (JAK2V617F) signaling, erythrocyte overproduction, and a propensity for thrombosis, progression to myelofibrosis, or acute leukemia. In this study, JAK2V617F expression by human hematopoietic progenitors promoted erythroid colony formation and erythroid engraftment in a bioluminescent xenogeneic immunocompromised mouse transplantation model. A selective JAK2 inhibitor, TG1 01348 (300 nM), significantly inhibited JAK2V617F(+) progenitor-derived colony formation as well as engraftment (120 mg/kg) in xenogeneic transplantation studies. TG1 01348 treatment decreased GATA-1 expression, which is associated with erythroid-skewing of JAK2V617F(+) progenitor differentiation, and inhibited STAT5 as well as GATA S310 phosphorylation. Thus, TG1 01348 may be an effective inhibitor of JAK2V617F(+) MPDs in clinical
引用
收藏
页码:321 / 330
页数:10
相关论文
共 39 条
[1]   POLYCYTHEMIA-VERA - STEM-CELL AND PROBABLE CLONAL ORIGIN OF DISEASE [J].
ADAMSON, JW ;
FIALKOW, PJ ;
MURPHY, S ;
PRCHAL, JF ;
STEINMANN, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 295 (17) :913-916
[2]   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].
Baxter, EJ ;
Scott, LM ;
Campbell, PJ ;
East, C ;
Fourouclas, N ;
Swanton, S ;
Vassiliou, GS ;
Bench, AJ ;
Boyd, EM ;
Curtin, N ;
Scott, MA ;
Erber, WN ;
Green, AR .
LANCET, 2005, 365 (9464) :1054-1061
[3]   Lentivirally transduced dendritic cells as a tool for cancer immunotherapy [J].
Breckpot, K ;
Dullaers, M ;
Bonehill, A ;
Van Meirvenne, S ;
Heirman, C ;
De Greef, C ;
van der Bruggen, P ;
Thielemans, K .
JOURNAL OF GENE MEDICINE, 2003, 5 (08) :654-667
[4]   UNREGULATED PROLIFERATION OF PRIMITIVE NEOPLASTIC PROGENITOR CELLS IN LONG-TERM POLYCYTHEMIA-VERA MARROW CULTURES [J].
CASHMAN, JD ;
EAVES, CJ ;
EAVES, AC .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (01) :87-91
[5]  
DAI CH, 1992, BLOOD, V80, P891
[6]   INDUCTION OF CHRONIC MYELOGENOUS LEUKEMIA IN MICE BY THE P210BCR/ABL GENE OF THE PHILADELPHIA-CHROMOSOME [J].
DALEY, GQ ;
VANETTEN, RA ;
BALTIMORE, D .
SCIENCE, 1990, 247 (4944) :824-830
[7]  
Deconinck AE, 2000, DEVELOPMENT, V127, P2031
[8]   Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].
Druker, Brian J. ;
Guilhot, Francois ;
O'Brien, Stephen G. ;
Gathmann, Insa ;
Kantarjian, Hagop ;
Gattermann, Norbert ;
Deininger, Michael W. N. ;
Silver, Richard T. ;
Goldman, John M. ;
Stone, Richard M. ;
Cervantes, Francisco ;
Hochhaus, Andreas ;
Powell, Bayard L. ;
Gabrilove, Janice L. ;
Rousselot, Philippe ;
Reiffers, Josy ;
Cornelissen, Jan J. ;
Hughes, Timothy ;
Agis, Hermine ;
Fischer, Thomas ;
Verhoef, Gregor ;
Shepherd, John ;
Saglio, Giuseppe ;
Gratwohl, Alois ;
Nielsen, Johan L. ;
Radich, Jerald P. ;
Simonsson, Bengt ;
Taylor, Kerry ;
Baccarani, Michele ;
So, Charlene ;
Letvak, Laurie ;
Larson, Richard A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417
[9]  
FIALKOW PJ, 1981, BLOOD, V58, P916
[10]   CHRONIC MYELOCYTIC-LEUKEMIA - CLONAL ORIGIN IN A STEM-CELL COMMON TO GRANULOCYTE, ERYTHROCYTE, PLATELET AND MONOCYTE-MACROPHAGE [J].
FIALKOW, PJ ;
JACOBSON, RJ ;
PAPAYANNOPOULOU, T .
AMERICAN JOURNAL OF MEDICINE, 1977, 63 (01) :125-130